bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S2 from Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases
Authors: Magee Michael S. , Abraham Tara S. , Baybutt Trevor R. , Flickinger John C. , Ridge Natalie A. , Marszalowicz Glen P. , Prajapati Priyanka , Hersperger Adam R. , Waldman Scott A. , Snook Adam E.
Published: April 2023

Figure S2 shows the scFv sequences used in the paper.
Figure S10 from Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases
Authors: Magee Michael S. , Abraham Tara S. , Baybutt Trevor R. , Flickinger John C. , Ridge Natalie A. , Marszalowicz Glen P. , Prajapati Priyanka , Hersperger Adam R. , Waldman Scott A. , Snook Adam E.
Published: April 2023

Figure S10 shows hGUCY2C-specific activation marker upregulation, cytokine production, and lysis by human T cells expressing 5F9.h28BBz.
Supplementary Figure 1 from Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer
Authors: Richman Lee P. , Vonderheide Robert H.
Published: April 2023

PDF file - 66K, Supplementary Figure 1. Crosslinking of CP-870,893 on surface of B cells and K32 cells.
Table S1 from Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade
Authors: Galanina Natalie , Goodman Aaron M. , Cohen Philip R. , Frampton Garrett M. , Kurzrock Razelle
Published: April 2023

Demographics and clinical characteristics
Table S3 from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Authors: Baumeister Susanne H. , Murad Joana , Werner Lillian , Daley Heather , Trebeden-Negre Helene , Gicobi Joanina K. , Schmucker Adam , Reder Jake , Sentman Charles L. , Gilham David E. , Lehmann Frédéric F. , Galinsky Ilene , DiPietro Heidi , Cummings Kristen , Munshi Nikhil C. , Stone Richard M. , Neuberg Donna S. , Soiffer Robert , Dranoff Glenn , Ritz Jerome , Nikiforow Sarah
Published: April 2023

Adverse Events
Figure S1 from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Authors: Baumeister Susanne H. , Murad Joana , Werner Lillian , Daley Heather , Trebeden-Negre Helene , Gicobi Joanina K. , Schmucker Adam , Reder Jake , Sentman Charles L. , Gilham David E. , Lehmann Frédéric F. , Galinsky Ilene , DiPietro Heidi , Cummings Kristen , Munshi Nikhil C. , Stone Richard M. , Neuberg Donna S. , Soiffer Robert , Dranoff Glenn , Ritz Jerome , Nikiforow Sarah
Published: April 2023

NKG2D-CAR T Cell Product Transduction Assessment
Table S1 from Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence
Authors: van den Hout Mari F.C.M. , Koster Bas D. , Sluijter Berbel J.R. , Molenkamp Barbara G. , van de Ven Rieneke , van den Eertwegh Alfons J.M. , Scheper Rik J. , van Leeuwen Paul A.M. , van den Tol M. Petrousjka , de Gruijl Tanja D.
Published: April 2023

Placebo-administered vs off-trial patients
Sup. Figure 2 from Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model
Authors: Poznanski Sophie M. , Nham Tina , Chew Marianne V. , Lee Amanda J. , Hammill Joanne A. , Fan Isabella Y. , Butcher Martin , Bramson Jonathan L. , Lee Dean A. , Hirte Hal W. , Ashkar Ali A.
Published: April 2023

Expression of NK cell activation and inhibitory ligands on resistant primary ovarian cancer cells.
Supplementary Figure Legend from mTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA
Authors: Diken Mustafa , Kreiter Sebastian , Vascotto Fulvia , Selmi Abderraouf , Attig Sebastian , Diekmann Jan , Huber Christoph , Türeci Özlem , Sahin Ugur
Published: April 2023

PDF file - 63K
Supplementary Figure 4 from Splenectomy Promotes Indirect Elimination of Intraocular Tumors by CD8+ T Cells That Is Associated with IFNγ- and Fas/FasL-Dependent Activation of Intratumoral Macrophages
Authors: Miller Maxine R. , Mandell Jonathan B. , Beatty Kelly M. , Harvey Stephen A.K. , Rizzo Michael J. , Previte Dana M. , Thorne Stephen H. , McKenna Kyle C.
Published: April 2023

Inflammatory gene expression within intraocular Luc-E.G7 tumors.
Supplementary Figures 1 - 2 from Spontaneous Peripheral T-cell Responses toward the Tumor-Associated Antigen Cyclin D1 in Patients with Clear Cell Renal Cell Carcinoma
Authors: Dannenmann Stefanie R. , Hermanns Thomas , Bransi Ali , Matter Claudia , von Boehmer Lotta , Stevanovic Stefan , Schraml Peter , Moch Holger , Knuth Alexander , van den Broek Maries
Published: April 2023

PDF file - 444K, Supplementary Figure S1: Cyclin D1-specific tetramer staining in PBMCs and TILs of ccRCC patients. Supplementary Figure S2: Imunoblotting for Cyclin D1 in sera of ccRCC patients.
Supplementary Table 1 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
Authors: Farsaci Benedetto , Donahue Renee N. , Coplin Michael A. , Grenga Italia , Lepone Lauren M. , Molinolo Alfredo A. , Hodge James W.
Published: April 2023

Effect of sunitinib alone, rMVA-Twist-TRICOM vaccine alone, or sunitinib in combination with vaccine on the phenotype of tumor-infiltrating MDSCs and TAMs in the 4T1 breast tumor model.
Data Supplement from Quantitative Effect of Natural Killer–Cell Licensing on Hepatocellular Carcinoma Recurrence after Curative Hepatectomy
Authors: Tanimine Naoki , Tanaka Yuka , Kobayashi Tsuyoshi , Tashiro Hirotaka , Miki Daiki , Imamura Michio , Aikata Hiroshi , Tanaka Junko , Chayama Kazuaki , Ohdan Hideki
Published: April 2023

Background characteristics of patients before and after propensity score matching for each functional compound KIR-HLA genotype are summarized.
Data Supplement from Quantitative Effect of Natural Killer–Cell Licensing on Hepatocellular Carcinoma Recurrence after Curative Hepatectomy
Authors: Tanimine Naoki , Tanaka Yuka , Kobayashi Tsuyoshi , Tashiro Hirotaka , Miki Daiki , Imamura Michio , Aikata Hiroshi , Tanaka Junko , Chayama Kazuaki , Ohdan Hideki
Published: April 2023

Propensity score matching was performed using nine variables (age, sex, etiology, tumor number, maximum diameter, histological differentiation, vascular invasion, satellite lesion, and surgical margin) for patients with at least three compound genotypes (highly licensed NK group) and patients with one or two compound genotypes (poorly licensed NK group). Background characteristics before and after matching are summarized.
Supplementary Figure 1 from Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens
Authors: Miller Aaron M. , Bahmanof Milad , Zehn Dietmar , Cohen Ezra E.W. , Schoenberger Stephen P.
Published: April 2023

Supplementary Figure 1
Table S1 from CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30+ and CD30− Embryonal Carcinoma via Antigen-Dependent and Fas/FasL Interactions
Authors: Hong Lee K. , Chen Yuhui , Smith Christof C. , Montgomery Stephanie A. , Vincent Benjamin G. , Dotti Gianpietro , Savoldo Barbara
Published: April 2023

List of differentially expressed genes
Figures S1-7 from CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30+ and CD30− Embryonal Carcinoma via Antigen-Dependent and Fas/FasL Interactions
Authors: Hong Lee K. , Chen Yuhui , Smith Christof C. , Montgomery Stephanie A. , Vincent Benjamin G. , Dotti Gianpietro , Savoldo Barbara
Published: April 2023

Supplementary Figures
Supplementary Table 1 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
Authors: Evgin Laura , Huff Amanda L. , Kottke Timothy , Thompson Jill , Molan Amy M. , Driscoll Christopher B. , Schuelke Matthew , Shim Kevin G. , Wongthida Phonphimon , Ilett Elizabeth J. , Smith Karen Kaluza , Harris Reuben S. , Coffey Matt , Pulido Jose S. , Pandha Hardev , Selby Peter J. , Harrington Kevin J. , Melcher Alan , Vile Richard G.
Published: April 2023

Suppl Table 1
Supplementary Figure 6 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
Authors: Evgin Laura , Huff Amanda L. , Kottke Timothy , Thompson Jill , Molan Amy M. , Driscoll Christopher B. , Schuelke Matthew , Shim Kevin G. , Wongthida Phonphimon , Ilett Elizabeth J. , Smith Karen Kaluza , Harris Reuben S. , Coffey Matt , Pulido Jose S. , Pandha Hardev , Selby Peter J. , Harrington Kevin J. , Melcher Alan , Vile Richard G.
Published: April 2023

Suppl Fig 6
Supplementary Table 1 from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
Authors: Laske Karoline , Shebzukhov Yuriy V. , Grosse-Hovest Ludger , Kuprash Dmitry V. , Khlgatian Svetlana V. , Koroleva Ekaterina P. , Sazykin Alexey Y. , Penkov Dmitry N. , Belousov Pavel V. , Stevanović Stefan , Vass Verona , Walter Steffen , Eisel David , Schmid-Horch Barbara D. , Nedospasov Sergei A. , Rammensee Hans-Georg , Gouttefangeas Cécile
Published: April 2023

PDF - 60KB, Supplementary Table 1: Serological reactivity of MO-TES391 assessed by SMARTA.
Supplementary Figure 4 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
Authors: Evgin Laura , Huff Amanda L. , Kottke Timothy , Thompson Jill , Molan Amy M. , Driscoll Christopher B. , Schuelke Matthew , Shim Kevin G. , Wongthida Phonphimon , Ilett Elizabeth J. , Smith Karen Kaluza , Harris Reuben S. , Coffey Matt , Pulido Jose S. , Pandha Hardev , Selby Peter J. , Harrington Kevin J. , Melcher Alan , Vile Richard G.
Published: April 2023

Suppl Fig 4
Supplementary Figure Legends from Alternative Variants of Human HYDIN Are Novel Cancer-Associated Antigens Recognized by Adaptive Immunity
Authors: Laske Karoline , Shebzukhov Yuriy V. , Grosse-Hovest Ludger , Kuprash Dmitry V. , Khlgatian Svetlana V. , Koroleva Ekaterina P. , Sazykin Alexey Y. , Penkov Dmitry N. , Belousov Pavel V. , Stevanović Stefan , Vass Verona , Walter Steffen , Eisel David , Schmid-Horch Barbara D. , Nedospasov Sergei A. , Rammensee Hans-Georg , Gouttefangeas Cécile
Published: April 2023

PDF - 88KB, Supplementary Figure Legends.
Supplementary Figure 2 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
Authors: Evgin Laura , Huff Amanda L. , Kottke Timothy , Thompson Jill , Molan Amy M. , Driscoll Christopher B. , Schuelke Matthew , Shim Kevin G. , Wongthida Phonphimon , Ilett Elizabeth J. , Smith Karen Kaluza , Harris Reuben S. , Coffey Matt , Pulido Jose S. , Pandha Hardev , Selby Peter J. , Harrington Kevin J. , Melcher Alan , Vile Richard G.
Published: April 2023

Suppl Fig 2
Supplementary Figure 3 from Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
Authors: Lanitis Evripidis , Poussin Mathilde , Klattenhoff Alex W. , Song Degang , Sandaltzopoulos Raphael , June Carl H. , Powell Daniel J.
Published: April 2023

PDF file - 1935K, Figure S3. shRNA based silencing of FRa in A1847 ovarian cancer cells. The parental human ovarian cancer cell line A1847 which expresses surface mesothelin and FRa protein was transduced with lentiviral particles encoding for an shRNA specific for silencing FRa gene expression (A1847 sh4 M+/F-). To determine surface antigen expression, cells were stained with an anti-mesothelin biobody reagent (P4 Bb) and anti-FRa antibody or proper isotype antibody controls. FRa expression was unaltered after engineering cells with control shRNA (A1847 csh M+/F+).
Figure S3 from Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence
Authors: van den Hout Mari F.C.M. , Koster Bas D. , Sluijter Berbel J.R. , Molenkamp Barbara G. , van de Ven Rieneke , van den Eertwegh Alfons J.M. , Scheper Rik J. , van Leeuwen Paul A.M. , van den Tol M. Petrousjka , de Gruijl Tanja D.
Published: April 2023

Major leukocyte subset frequencies in melanoma SLN grouped by stage
Figure S1 from Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence
Authors: van den Hout Mari F.C.M. , Koster Bas D. , Sluijter Berbel J.R. , Molenkamp Barbara G. , van de Ven Rieneke , van den Eertwegh Alfons J.M. , Scheper Rik J. , van Leeuwen Paul A.M. , van den Tol M. Petrousjka , de Gruijl Tanja D.
Published: April 2023

Flowcytometric gating strategies for regulatory T cells in the melanoma sentinel lymph node and correlation between Treg frequencies in the melanoma SLN as measured by FoxP3 or by CTLA4 expression
Supplementary Figures 1 - 6 from T Cells Bearing a Chimeric Antigen Receptor against Prostate-Specific Membrane Antigen Mediate Vascular Disruption and Result in Tumor Regression
Authors: Santoro Stephen P. , Kim Soorin , Motz Gregory T. , Alatzoglou Dimitrios , Li Chunsheng , Irving Melita , Powell Daniel J. , Coukos George
Published: April 2023

Figure S1: CAR surface expression tightly correlates with eGFP reporter expression. Figure S2: Bcl-xL induction in response to CAR T-cell activation. Figure S3: PSMA is expressed heterogeneously on tumor blood vessels. Figure S4: P28BBζ T cell-mediated regression of large PSMA+ hemangiomas. Figure S5: P28BBζ T cells eliminate PSMA+ tumor blood vessels and elicit tumor regression in MS1PSMA/ID8 tumors. Figure S6: Comparison of single vs. multiple injections of P28BBζ T cells.
Supplemental Figure Legends from T Cells Bearing a Chimeric Antigen Receptor against Prostate-Specific Membrane Antigen Mediate Vascular Disruption and Result in Tumor Regression
Authors: Santoro Stephen P. , Kim Soorin , Motz Gregory T. , Alatzoglou Dimitrios , Li Chunsheng , Irving Melita , Powell Daniel J. , Coukos George
Published: April 2023

Supplemental Figure Legends
Supplementary Figures 1 through 7 from Antigen-Specific Culture of Memory-like CD8 T Cells for Adoptive Immunotherapy
Authors: Litterman Adam J. , Zellmer David M. , LaRue Rebecca S. , Jameson Stephen C. , Largaespada David A.
Published: April 2023

PDF - 930K, Supplementary Figure 1. Individual modifications to culture medium yield a fraction of CD62L+ cells in extended culture Supplementary Figure 2. Cells cultured in cocktail containing medium have greater viability. Supplementary Figure 3. Expansion of OT-I CD8 T cells in IL-2 and cocktail containing medium. Supplementary Figure 4. Comparison of gene expression profiles between antigen-specific cell culture and a natural immune response. Supplementary Figure 5. Expansion of Ova-specific CD8 T cells from C57BL/6 mouse after dextramer pulldown. Supplementary Figure 6. Expansion of neo-antigen-specific CD8 T cells from healthy human PBMC after dextramer pulldown. Supplementary Figure 7. Polyclonal expanded CD8 T cells rapidly become CD45RO+.
Suppl fig 5 from Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing
Authors: Brandsma Arianne M. , ten Broeke Toine , Nederend Maaike , Meulenbroek Laura A.P.M. , van Tetering Geert , Meyer Saskia , Jansen J.H. Marco , Beltrán Buitrago M. Alejandra , Nagelkerke Sietse Q. , Németh István , Ubink Ruud , Rouwendal Gerard , Lohse Stefan , Valerius Thomas , Leusen Jeanette H.W. , Boross Peter
Published: April 2023

PMN-mediated cytotoxicity is not increased by the combination of IgG and IgA against two targets. (A) Pooled data (8 donors) from ADCC assays were performed using purified PMNs isolated by Ficoll/Histopaque separation and A431-HER2 target cells either with cetuximab, or IgA2-HER2 or both mAbs (Mean {plus minus} SEM). (B) Maximal specific lysis plotted from eight donors (median, box extends from the 25th to 75th percentiles, whiskers to min and max; ***: p<0.001; ANOVA, Tukey's multiple comparison test).
Suppl fig 2 from Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing
Authors: Brandsma Arianne M. , ten Broeke Toine , Nederend Maaike , Meulenbroek Laura A.P.M. , van Tetering Geert , Meyer Saskia , Jansen J.H. Marco , Beltrán Buitrago M. Alejandra , Nagelkerke Sietse Q. , Németh István , Ubink Ruud , Rouwendal Gerard , Lohse Stefan , Valerius Thomas , Leusen Jeanette H.W. , Boross Peter
Published: April 2023

Binding of cetuximab and trastuzumab to different tumor cell lines. To study cytotoxicity of both EGFR and HER2 mAbs we established A431-HER2 cells by retrovirally transducing A431 cells with human HER2. HER2 expression on A431-HER2 cells was comparable to SK-BR-3 cells, whereas EGFR expression did not change compared to parental A431 line. A431, A431-HER2 and SK-BR-3 cells were incubated with trastuzumab (A) or cetuximab (B) followed by staining with FITC-labeled anti-human IgG mAb.
Supplementary Figure Legend from Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer
Authors: Rautela Jai , Baschuk Nikola , Slaney Clare Y. , Jayatilleke Krishnath M. , Xiao Kun , Bidwell Bradley N. , Lucas Erin C. , Hawkins Edwin D. , Lock Peter , Wong Christina S. , Chen Weisan , Anderson Robin L. , Hertzog Paul J. , Andrews Daniel M. , Möller Andreas , Parker Belinda S.
Published: April 2023

Supplementary Figure Legend from Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer
Supplementary Figure 4 from Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer
Authors: Rautela Jai , Baschuk Nikola , Slaney Clare Y. , Jayatilleke Krishnath M. , Xiao Kun , Bidwell Bradley N. , Lucas Erin C. , Hawkins Edwin D. , Lock Peter , Wong Christina S. , Chen Weisan , Anderson Robin L. , Hertzog Paul J. , Andrews Daniel M. , Möller Andreas , Parker Belinda S.
Published: April 2023

Anti-proliferative effects and production of type-I IFN by balb/c syngeneic breast tumor cell lines.
Supplementary Figure 2 from Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer
Authors: Rautela Jai , Baschuk Nikola , Slaney Clare Y. , Jayatilleke Krishnath M. , Xiao Kun , Bidwell Bradley N. , Lucas Erin C. , Hawkins Edwin D. , Lock Peter , Wong Christina S. , Chen Weisan , Anderson Robin L. , Hertzog Paul J. , Andrews Daniel M. , Möller Andreas , Parker Belinda S.
Published: April 2023

IL-2 stimulated NK cells derived from Ifnar1-/- or WT mice have comparable cytotoxicity against syngeneic breast tumor lines.
Figure S3 from Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC
Authors: Brockwell Natasha K. , Owen Katie L. , Zanker Damien , Spurling Alex , Rautela Jai , Duivenvoorden Hendrika M. , Baschuk Nikola , Caramia Franco , Loi Sherene , Darcy Phillip K. , Lim Elgene , Parker Belinda S.
Published: April 2023

The effect of combination treatment on T cell activation
Supplementary Methods from Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes
Authors: Klevorn Lauryn E. , Berrien-Elliott Melissa M. , Yuan Jinyun , Kuehm Lindsey M. , Felock Gregory D. , Crowe Sean A. , Teague Ryan M.
Published: April 2023

Supplementary Methods
Supplementary Figures 1 through 6, and Supplementary Tables 1 through 3 from Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival
Authors: Miller Natalie J. , Church Candice D. , Dong Lichun , Crispin David , Fitzgibbon Matthew P. , Lachance Kristina , Jing Lichen , Shinohara Michi , Gavvovidis Ioannis , Willimsky Gerald , McIntosh Martin , Blankenstein Thomas , Koelle David M. , Nghiem Paul
Published: April 2023

Figure S1. KLL-specific TCR diversity in PBMC is not correlated with the magnitude of KLL-specific responses. Figure S2. Clonality of KLL-specific T cell repertoire in PBMC of MCC patients does not correlate with disease outcome. Figure S3. T cell infiltrate of tumor samples characterized by TCR repertoire and IHC. Figure S4. Clonality of the T cell repertoire within tumors of MCC patients does not correlate with disease outcome. Figure S5. Percentage and number of KLL-specific clonotypes amid tumors. Table S1. Homologs to the CT15-23 (KLLEIAPNC) epitope from other polyomaviruses. Table S2. Characteristics of MCC Patients with A*02/KLL Tetramer+T cells. Table S3. List of all TCRβ clonotypes resolved from HLA-A*02:01/KLL-tetramer sorted T cells, annotated by patient.
Supplementary Figure S5 from Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes
Authors: Klevorn Lauryn E. , Berrien-Elliott Melissa M. , Yuan Jinyun , Kuehm Lindsey M. , Felock Gregory D. , Crowe Sean A. , Teague Ryan M.
Published: April 2023

Human IL-2c treatment does not alter CD4 and CD8 T cell frequencies in humanized mice
Supplementary Table 1 from Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer
Authors: Bransi Ali , Salgado Oscar Camilo , Beffinger Michal , Milo Karim , Silina Karina , Yagita Hideo , Becher Burkhard , Knuth Alexander , van den Broek Maries
Published: April 2023

Impact of various immune interventions on preventing tolerance and improving TCR-I cells proliferation and function.
Supplementary Figure S3 from Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes
Authors: Klevorn Lauryn E. , Berrien-Elliott Melissa M. , Yuan Jinyun , Kuehm Lindsey M. , Felock Gregory D. , Crowe Sean A. , Teague Ryan M.
Published: April 2023

T cells treated with IL-2c and IL-15c produce similar levels of cytokine by MFI
Supplementary Figure S1 from Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes
Authors: Klevorn Lauryn E. , Berrien-Elliott Melissa M. , Yuan Jinyun , Kuehm Lindsey M. , Felock Gregory D. , Crowe Sean A. , Teague Ryan M.
Published: April 2023

Checkpoint blockade fails to rescue persistence of tolerant CD8+ T cells
Supplementary Figure Legends from Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer
Authors: Bransi Ali , Salgado Oscar Camilo , Beffinger Michal , Milo Karim , Silina Karina , Yagita Hideo , Becher Burkhard , Knuth Alexander , van den Broek Maries
Published: April 2023

Legends for supplementary figures S1-S7
Supplementary Table 1 from Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion
Authors: De Veirman Kim , De Beule Nathan , Maes Ken , Menu Eline , De Bruyne Elke , De Raeve Hendrik , Fostier Karel , Moreaux Jérôme , Kassambara Alboukadel , Hose Dirk , Heusschen Roy , Eriksson Helena , Vanderkerken Karin , Van Valckenborgh Els
Published: April 2023

Primer sequences of genes evaluated by qRT-PCR.
Supplementary Table S1 from Hypomethylation of the Treg-Specific Demethylated Region in FOXP3 Is a Hallmark of the Regulatory T-cell Subtype in Adult T-cell Leukemia
Authors: Shimazu Yayoi , Shimazu Yutaka , Hishizawa Masakatsu , Hamaguchi Masahide , Nagai Yuya , Sugino Noriko , Fujii Sumie , Kawahara Masahiro , Kadowaki Norimitsu , Nishikawa Hiroyoshi , Sakaguchi Shimon , Takaori-Kondo Akifumi
Published: April 2023

Supplementary Table S1. Patients' characteristics
Figure S1 from Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion
Authors: De Veirman Kim , De Beule Nathan , Maes Ken , Menu Eline , De Bruyne Elke , De Raeve Hendrik , Fostier Karel , Moreaux Jérôme , Kassambara Alboukadel , Hose Dirk , Heusschen Roy , Eriksson Helena , Vanderkerken Karin , Van Valckenborgh Els
Published: April 2023

ABR-238901 did not reduce viability of MDSC.
Supplementary Figure Legends from Hypomethylation of the Treg-Specific Demethylated Region in FOXP3 Is a Hallmark of the Regulatory T-cell Subtype in Adult T-cell Leukemia
Authors: Shimazu Yayoi , Shimazu Yutaka , Hishizawa Masakatsu , Hamaguchi Masahide , Nagai Yuya , Sugino Noriko , Fujii Sumie , Kawahara Masahiro , Kadowaki Norimitsu , Nishikawa Hiroyoshi , Sakaguchi Shimon , Takaori-Kondo Akifumi
Published: April 2023

Supplementary Figure Legends
Supplementary Methods from Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
Authors: Müller Philipp , Martin Kea , Theurich Sebastian , Schreiner Jens , Savic Spasenija , Terszowski Grzegorz , Lardinois Didier , Heinzelmann-Schwarz Viola A. , Schlaak Max , Kvasnicka Hans-Michael , Spagnoli Giulio , Dirnhofer Stephan , Speiser Daniel E. , von Bergwelt-Baildon Michael , Zippelius Alfred
Published: April 2023

PDF file - 97K
Supplementary Fig. S3 from Regulatory T Cells from Colon Cancer Patients Inhibit Effector T-cell Migration through an Adenosine-Dependent Mechanism
Authors: Sundström Patrik , Stenstad Hanna , Langenes Veronica , Ahlmanner Filip , Theander Lisa , Ndah Tapuka Gordon , Fredin Kamilla , Börjesson Lars , Gustavsson Bengt , Bastid Jérémy , Quiding-Järbrink Marianne
Published: April 2023

This supplementary figure shows CD73 expression on endothelial cells and monocytes.
Supplementary Fig. S2 from Regulatory T Cells from Colon Cancer Patients Inhibit Effector T-cell Migration through an Adenosine-Dependent Mechanism
Authors: Sundström Patrik , Stenstad Hanna , Langenes Veronica , Ahlmanner Filip , Theander Lisa , Ndah Tapuka Gordon , Fredin Kamilla , Börjesson Lars , Gustavsson Bengt , Bastid Jérémy , Quiding-Järbrink Marianne
Published: April 2023

This supplementary figure shows CD73 expression by circulating (A) and colon (B) CD4+ T cells.
Data Supplement from Cytotoxic T Lymphocytes Block Tumor Growth Both by Lytic Activity and IFNγ-Dependent Cell-Cycle Arrest
Authors: Matsushita Hirokazu , Hosoi Akihiro , Ueha Satoshi , Abe Jun , Fujieda Nao , Tomura Michio , Maekawa Ryuji , Matsushima Kouji , Ohara Osamu , Kakimi Kazuhiro
Published: April 2023

Adoptive CTL transfer therapy in B16-fucciÎ”IC tumor-bearing mice.
Data Supplement from Cytotoxic T Lymphocytes Block Tumor Growth Both by Lytic Activity and IFNγ-Dependent Cell-Cycle Arrest
Authors: Matsushita Hirokazu , Hosoi Akihiro , Ueha Satoshi , Abe Jun , Fujieda Nao , Tomura Michio , Maekawa Ryuji , Matsushima Kouji , Ohara Osamu , Kakimi Kazuhiro
Published: April 2023

Effect of IFN-Î³ plus TNF-Î± on B16 tumor cells.
Supplementary Figures 1 - 2, Tables 1 - 2 from Tumor MHC Class I Expression Improves the Prognostic Value of T-cell Density in Resected Colorectal Liver Metastases
Authors: Turcotte Simon , Katz Steven C. , Shia Jinru , Jarnagin William R. , Kingham T. Peter , Allen Peter J. , Fong Yuman , D'Angelica Michael I. , DeMatteo Ronald P.
Published: April 2023

PDF file - 182K, Table S1 shows the correlation between all immune markers expression tested; Table S2 shows the lack of correlation between the favorable immune score and clinicopathologic characteristics. Figure S1 illustrates the quantification method for MHC Class I and Beta 2-microglobulin; Figure S2 shows the association between the immune score and the Clinical Risk Score.
Supplementary Table S1 from Mutation Drivers of Immunological Responses to Cancer
Authors: Porta-Pardo Eduard , Godzik Adam
Published: April 2023

Supplementary Table S1 - Regions identified by domainXplorer as associated with changes in immune infiltrate Columns are as follows: Symbol: official gene symbol Region: Region of the protein involved where ENSPXXXX is the protein isoform, ND/PFXXX/IDR is the type of region (ND: new domain / PF: PFAM domain / IDR: disordered region) and the numbers are the coordinates of the start and end of the region p1: p value of the linear regression model p2: p value of the wilcoxon test comparing samples with mutations in the region and samples with no mutations in the protein p3: p value of the wilcoxon test comparing samples with mutations in the region and samples with other mutations in the protein Mean F: Mean ESTIMATE immune score in samples with mutations in the region Mean OG: Mean ESTIMATE immune score in samples with mutations in the other regions of the gene Mean WT: Mean ESTIMATE immune score in samples with no mutations in the protein
Table S1 from Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer
Authors: Mulligan Anna Marie , Pinnaduwage Dushanthi , Tchatchou Sandrine , Bull Shelley B. , Andrulis Irene L.
Published: April 2023

Table S1 gives the relative risks by univariate Cox proportional hazards model of DFS for di- categorization (low, high) of T-bet for several (10, 15, 20, 25, 30) cut points. T-bet-/low was associated with reduced DFS at cut points 15, 25, and 30 as relative risks and p-values suggested.
Figure S1b from Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer
Authors: Mulligan Anna Marie , Pinnaduwage Dushanthi , Tchatchou Sandrine , Bull Shelley B. , Andrulis Irene L.
Published: April 2023

This figure compares K-M curves of DFS by di- and tri- categorizations of T-bet for the cut point at 30. It is evident in the three-level KM plots that the absent and low count groups of T-bet are indistinguishable for the cut-point 30 to define the high versus the low count group of T-bet.
Supplementary Figures from Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma
Authors: Kamiya Takahiro , Chang Yu-Hsiang , Campana Dario
Published: April 2023

Supplementary Figures S1-S9 which show additional data regarding the cytotxicity of NK cells against HCC cell lines in vitro and in vivo, the activity of sorafenib against HCC cell lines, the expression of HLA-Class I and NKG2D ligands in HCC cell lines, and the expression of NKG2D on NK cells transduced with NKG2D-CD3zeta-DAP10 receptors.
Supplemental Figure 4 from Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity
Authors: Wiehagen Karla R. , Girgis Natasha M. , Yamada Douglas H. , Smith Andressa A. , Chan Szeman Ruby , Grewal Iqbal S. , Quigley Michael , Verona Raluca I.
Published: April 2023

S4. The cytokine milieu is more inflammatory in anti-CD40 and combination treated tumors.
Supplemental Figure 3 from Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity
Authors: Wiehagen Karla R. , Girgis Natasha M. , Yamada Douglas H. , Smith Andressa A. , Chan Szeman Ruby , Grewal Iqbal S. , Quigley Michael , Verona Raluca I.
Published: April 2023

S3. Increased frequencies of effector CD8+ T cells in dLN and tumor after combination treatment.
Supplemental Figure 1 from Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity
Authors: Wiehagen Karla R. , Girgis Natasha M. , Yamada Douglas H. , Smith Andressa A. , Chan Szeman Ruby , Grewal Iqbal S. , Quigley Michael , Verona Raluca I.
Published: April 2023

S1. CSF-1R is most highly expressed on TAMs in CT26 tumors.
Supplementary Figures 1 through 5, Supplementary Tables 1 through 4, and Supplementary Methods from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Authors: Mosely Suzanne I.S. , Prime John E. , Sainson Richard C.A. , Koopmann Jens-Oliver , Wang Dennis Y.Q. , Greenawalt Danielle M. , Ahdesmaki Miika J. , Leyland Rebecca , Mullins Stefanie , Pacelli Luciano , Marcus Danielle , Anderton Judith , Watkins Amanda , Coates Ulrichsen Jane , Brohawn Philip , Higgs Brandon W. , McCourt Matthew , Jones Hazel , Harper James A. , Morrow Michelle , Valge-Archer Viia , Stewart Ross , Dovedi Simon J. , Wilkinson Robert W.
Published: April 2023

Supplementary Figure S1: Summary of experiments Supplementary Figure S2: Gating strategy Supplementary Figure S3:Profiling by array CGH, whole-exome and targeted sequencing Supplementary Figure S4: Comparison of mutational profiles of murine syngeneic tumor cell lines and TCGA patient tumors Supplementary Figure S5: Differentially-expressed gene-sets in lymph node and spleen Supplementary Table S1: Cell line details Supplementary Table S2: Copy Number Variation Supplementary Table S3: List of 64 genes investigated by targeted sequencing Supplementary Table S4: Fluorescent antibodies used Supplementary Methods: Linear mixed-effect model
Supplementary Figures 1 through 4 from Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers
Authors: Moore Ellen C. , Cash Harrison A. , Caruso Andria M. , Uppaluri Ravindra , Hodge James W. , Van Waes Carter , Allen Clint T.
Published: April 2023

Contains supplemental figures 1 through 4 and their corresponding legends. Suppl Fig 1 demonstrates summary growth curves for in vivo MOC1 and MOC2 experiments. Suppl Fig 2 is validation of p15E antigen expression in MOC cell lines. Supple Fig 3 demonstrates immune correlative data for treated MOC2-tumor nearing mice. Finally, Suppl Fig 4 is validation of our tumor and spleen cellular depletion with our described methods.
Supplemental Figures 1 - 10 from Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease
Authors: Clancy-Thompson Eleanor , Perekslis Thomas J. , Croteau Walburga , Alexander Matthew P. , Chabanet Tamer B. , Turk Mary Jo , Huang Yina H. , Mullins David W.
Published: April 2023

Supplemental Figure 1: Mice were given intravenous B16 injection on day 0. Supplemental Figure 2: Mice were given intravenous B16 injection on day 0.Supplemental Figure 3: Induced Braf/Pten tumors were harvested at 25 days or 40 days post-induction, corresponding to early (~5mm2) or late (~25mm2) tumors. Supplemental Figure 4: Chemokine production in melanoma. Supplemental Figure 5: Representative gating strategy for extracellular and intracellular staining. Supplemental Figure 6: Representative flow cytometry of Pmel CD8+ T cells stained for CD8 and CXCR3 after in vitro activation but before adoptive transfer. Supplemental Figure 7: Mice were given intravenous B16 injection on day 0. Supplemental Figure 8: Splenocytes were harvested from Pmel and Pmel-CXCR3-/- mice. Supplemental Figure 9: Naïve mice were injected (I.P.) with 50mg/kg aminophylline three times over the course of nine days. Supplemental Figure 10: Regulatory T cells in advanced melanomas express CD73.
Supplemental Figure 2 from Mast Cells Boost Myeloid-Derived Suppressor Cell Activity and Contribute to the Development of Tumor-Favoring Microenvironment
Authors: Danelli Luca , Frossi Barbara , Gri Giorgia , Mion Francesca , Guarnotta Carla , Bongiovanni Lucia , Tripodo Claudio , Mariuzzi Laura , Marzinotto Stefania , Rigoni Alice , Blank Ulrich , Colombo Mario P. , Pucillo Carlo E.
Published: April 2023

IFN- γ role in the regulation of M-MDSC:MC suppressive axis.
Supplementary Table S1 from Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Authors: Noguchi Takuro , Ward Jeffrey P. , Gubin Matthew M. , Arthur Cora D. , Lee Sang Hun , Hundal Jasreet , Selby Mark J. , Graziano Robert F. , Mardis Elaine R. , Korman Alan J. , Schreiber Robert D.
Published: April 2023

Supplementary Table S1. Staining panels for comprehensive analysis of cell types expressing PD-L1.
Figure Legends for Supplementary Data from Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Authors: Noguchi Takuro , Ward Jeffrey P. , Gubin Matthew M. , Arthur Cora D. , Lee Sang Hun , Hundal Jasreet , Selby Mark J. , Graziano Robert F. , Mardis Elaine R. , Korman Alan J. , Schreiber Robert D.
Published: April 2023

Figure Legends for Supplementary Data
Supplemental Figures 1-4 from PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells
Authors: Mahoney Kathleen M. , Sun Heather , Liao Xiaoyun , Hua Ping , Callea Marcella , Greenfield Edward A. , Hodi F. Stephen , Sharpe Arlene H. , Signoretti Sabina , Rodig Scott J. , Freeman Gordon J.
Published: April 2023

Supplemental Figure 1. Western blotting of PD-L1 mAbs. Supplemental Figure 2. Western blotting of PD-L1 mAbs specific for the cytoplasmic domain. Supplemental Figure 3. 300.19 and stably transfected 300.19 expressing human PD-L1 were stained with 9A11 mAb. Supplemental Figure 4. Isotype control staining. Staining of the same nasopharyngeal carcinoma used in Figure 4 with isotype control antibody at the same concentration as its respective mouse or rabbit PD-L1 mAb.
Supplemental Figure Legends from Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies
Authors: Hossain Fokhrul , Al-Khami Amir A. , Wyczechowska Dorota , Hernandez Claudia , Zheng Liqin , Reiss Krzystoff , Valle Luis Del , Trillo-Tinoco Jimena , Maj Tomasz , Zou Weiping , Rodriguez Paulo C. , Ochoa Augusto C.
Published: April 2023

Supplemental Figure Legends
Supplemental Figure 4 from Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies
Authors: Hossain Fokhrul , Al-Khami Amir A. , Wyczechowska Dorota , Hernandez Claudia , Zheng Liqin , Reiss Krzystoff , Valle Luis Del , Trillo-Tinoco Jimena , Maj Tomasz , Zou Weiping , Rodriguez Paulo C. , Ochoa Augusto C.
Published: April 2023

Supplemental Figure 4: FAO inhibitors do not affect the growth of tumor cells, cancer stem cells (spheres) or the expression of cancer stem-cell markers.
Supplemental Figure 3 from Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies
Authors: Hossain Fokhrul , Al-Khami Amir A. , Wyczechowska Dorota , Hernandez Claudia , Zheng Liqin , Reiss Krzystoff , Valle Luis Del , Trillo-Tinoco Jimena , Maj Tomasz , Zou Weiping , Rodriguez Paulo C. , Ochoa Augusto C.
Published: April 2023

Supplemental Figure 3: Etomoxir decreases CPT-1 enzymatic activity in vivo, decreases Treg accumulation in spleens.
Supplementary Methods from Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Authors: Weide Benjamin , Eigentler Thomas K. , Pflugfelder Annette , Zelba Henning , Martens Alexander , Pawelec Graham , Giovannoni Leonardo , Ruffini Pier Adelchi , Elia Giuliano , Neri Dario , Gutzmer Ralf , Becker Jürgen C. , Garbe Claus
Published: April 2023

PDF file - 81K, Detailed clinical course of disease in representative patients.
Supplementary Fig. S8 from Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
Authors: Manuel Edwin R. , Chen Jeremy , D'Apuzzo Massimo , Lampa Melanie G. , Kaltcheva Teodora I. , Thompson Curtis B. , Ludwig Thomas , Chung Vincent , Diamond Don J.
Published: April 2023

Detection of PMN in extracted tumors of PEGPH20/shIDO-ST treated mice. Mice treated with PEGPH20/shScr-ST or PEGPH20/shIDO-ST were euthanized and tumors extracted 96 hours post-ST treatment. One hour prior to euthanization, mice were injected with NS-NIR reagent. Tumors were imaged using a Xenogen 100 equipped with an ICG filter set.
Supplementary Figure Legend from Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
Authors: Derks Sarah , Nason Katie S. , Liao Xiaoyun , Stachler Matthew D. , Liu Kevin X. , Liu Jie Bin , Sicinska Ewa , Goldberg Michael S. , Freeman Gordon J. , Rodig Scott J. , Davison Jon M. , Bass Adam J.
Published: April 2023

Supplementary Figure Legend
Supplementary Figure S3 from Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness
Authors: Miller Lance D. , Chou Jeff A. , Black Michael A. , Print Cristin , Chifman Julia , Alistar Angela , Putti Thomas , Zhou Xiaobo , Bedognetti Davide , Hendrickx Wouter , Pullikuth Ashok , Rennhack Jonathan , Andrechek Eran R. , Demaria Sandra , Wang Ena , Marincola Francesco M.
Published: April 2023

Differential abundance of immune cell infiltrate in FID and PID breast tumors.
Supplemental Table And Figure Legends from CARD9 Promotes Sex-Biased Colon Tumors in the APCmin Mouse Model
Authors: Leo Vonny I. , Tan Sze Huey , Bergmann Hanna , Cheah Peh Yean , Chew Min Hoe , Lim Kiat Hon , Ruland Jürgen , Reilly Patrick T.
Published: April 2023

Supplemental Table S1 and Figure Legends for Figures S1 and S2
Supplementary Figure 1 from Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer
Authors: Kates Max , Nirschl Thomas , Sopko Nikolai A. , Matsui Hotaka , Kochel Christina M. , Reis Leonardo O. , Netto George J. , Hoque Mohammad O. , Hahn Noah M. , McConkey David J. , Baras Alex S. , Drake Charles G. , Bivalacqua Trinity J.
Published: April 2023

Flow cytometry gating strategy is outlined. After digestion of tumor infiltrated bladders, samples yielded 1-2 million cells per bladder. A) Live T lymphocyte subpopulations were then gated from spleen tissue, and B) bladder T cells of interest were then selected.
Supplementary Figure 3 from Estradiol Promotes Breast Cancer Cell Migration via Recruitment and Activation of Neutrophils
Authors: Vazquez Rodriguez Gabriela , Abrahamsson Annelie , Jensen Lasse Dahl Ejby , Dabrosin Charlotta
Published: April 2023

ICAM expression in MCF-7 and MDA-MB-231 mammospheres.
Supplemental figures 1 - 3 from Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers
Authors: Gross Stefanie , Lennerz Volker , Gallerani Elisa , Mach Nicolas , Böhm Steffen , Hess Dagmar , von Boehmer Lotta , Knuth Alexander , Ochsenbein Adrian , Gnad-Vogt Ulrike , Forssmann Ulf , Woelfel Thomas , Kaempgen Eckhart
Published: April 2023

(1) Gating strategy, (2) representative examples of the time course of spCD4 responses, (3) individual cytokine profile and magnitude of spCD4 responses of all patients with detected spCD4 T cell response
Supplemental Figure 6 from Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations
Authors: Sanders Kiah L. , Fox Barbara A. , Bzik David J.
Published: April 2023

Systemic IFN-γ and frequency of IFN-γ by CD4 and CD8 T cells.
Supplemental Table 6 from Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance
Authors: Doedens Andrew L. , Rubinstein Mark P. , Gross Emilie T. , Best J. Adam , Craig David H. , Baker Megan K. , Cole David J. , Bui Jack D. , Goldrath Ananda W.
Published: April 2023

Transcripts up-regulated {greater than or equal to}2-fold in PyMT tumor versus splenic CD8+ T cells.
Supplementary Figure Legends from Immune Cell Gene Signatures for Profiling the Microenvironment of Solid Tumors
Authors: Nirmal Ajit J. , Regan Tim , Shih Barbara B. , Hume David A. , Sims Andrew H. , Freeman Tom C.
Published: April 2023

Supplementary Figure Legends
Figure S3 from Immune Cell Gene Signatures for Profiling the Microenvironment of Solid Tumors
Authors: Nirmal Ajit J. , Regan Tim , Shih Barbara B. , Hume David A. , Sims Andrew H. , Freeman Tom C.
Published: April 2023

Supplementary Figure 3
Supplementary Materials and Methods and Supplementary Figures 1 through 4 from Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells
Authors: Dovedi Simon J. , Lipowska-Bhalla Grazyna , Beers Stephen A. , Cheadle Eleanor J. , Mu Lijun , Glennie Martin J. , Illidge Timothy M. , Honeychurch Jamie
Published: April 2023

Contains additional information methods data associated with accompanying supplemental figures, and additional data on in vivo studies, including information on experimental animals, housing and sample size. Contains 4 supplemental figures demonstrating: Figure 1, the cytotoxicity of clodronate liposomes against macrophages and tumor cells in vitro; Figure 2, that depletion of DC abrogates the priming of tumor-antigen specific CD8 T-cells following radiation and anti-CD40 mAb therapy; Figure 3, the impact of depletion of CD169 macrophages on radiation and anti-CD40 mAb therapy; Figure 4, combination radiation and R848 (TLR-7 agonist)leads to priming of tumor-specific CD8 T-cells.
Figure S2 from Natural Killer T-cell Immunotherapy in Combination with Chemotherapy-Induced Immunogenic Cell Death Targets Metastatic Breast Cancer
Authors: Gebremeskel Simon , Lobert Lynnea , Tanner Kaitlyn , Walker Brynn , Oliphant Tora , Clarke Livia E. , Dellaire Graham , Johnston Brent
Published: April 2023

Gemcitabine and cyclophosphamide do not activate NKT cells
Supplementary Figure legend from Cross-Presentation of the Oncofetal Tumor Antigen 5T4 from Irradiated Prostate Cancer Cells—A Key Role for Heat-Shock Protein 70 and Receptor CD91
Authors: Salimu Josephine , Spary Lisa K. , Al-Taei Saly , Clayton Aled , Mason Malcolm D. , Staffurth John , Tabi Zsuzsanna
Published: April 2023

Supplementary Figure legend
Figure S1 from Natural Killer T-cell Immunotherapy in Combination with Chemotherapy-Induced Immunogenic Cell Death Targets Metastatic Breast Cancer
Authors: Gebremeskel Simon , Lobert Lynnea , Tanner Kaitlyn , Walker Brynn , Oliphant Tora , Clarke Livia E. , Dellaire Graham , Johnston Brent
Published: April 2023

Cell death pathways induced by gemcitabine and mafosfamide
Supplemental Figure S6 from Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
Authors: Long Adrienne H. , Highfill Steven L. , Cui Yongzhi , Smith Jillian P. , Walker Alec J. , Ramakrishna Sneha , El-Etriby Rana , Galli Susana , Tsokos Maria G. , Orentas Rimas J. , Mackall Crystal L.
Published: April 2023

ATRA treatment does not induce FOXP3 expression in GD2-CAR T cells in NSG mice.
Supplemental Figure S4 from Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
Authors: Long Adrienne H. , Highfill Steven L. , Cui Yongzhi , Smith Jillian P. , Walker Alec J. , Ramakrishna Sneha , El-Etriby Rana , Galli Susana , Tsokos Maria G. , Orentas Rimas J. , Mackall Crystal L.
Published: April 2023

ATRA treatment does not improve GD2-CAR T cell efficacy or persistence in setting of Kelly neuroblastoma tumors.
Supplementary figures 1 through 15 and Supplementary Tables 1 through 5 from Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor
Authors: Pasetto Anna , Gros Alena , Robbins Paul F. , Deniger Drew C. , Prickett Todd D. , Matus-Nicodemos Rodrigo , Douek Daniel C. , Howie Bryan , Robins Harlan , Parkhurst Maria R. , Gartner Jared , Trebska-McGowan Katarzyna , Crystal Jessica S. , Rosenberg Steven A.
Published: April 2023

Gating strategy, Shannon entropy, PD-1 expression, additional co-culture data, primers sequence, Frequency of the top 10 CD8+PD-1+ TCRB in bulk unsorted TIL and sorted TIL subsets, Retrospective analysis of pairing the most frequent TCRB in the CD8+PD-1+ TIL subset with the most frequent TCRA from the same subset, Method of identification of TCR pairs, TCR expression on genetically engineered PBL.
Supplementary Figure 1 from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization
Authors: Ohmatsu Hanako , Humme Daniel , Gulati Nicholas , Gonzalez Juana , Möbs Markus , Suárez-Fariñas Mayte , Cardinale Irma , Mitsui Hiroshi , Guttman-Yassky Emma , Sterry Wolfram , Krueger James G.
Published: April 2023

PDF file - 240K, IL-32 production is not restricted to already known T-cell subsets.
Supplementary Figures 1 - 2, Tables 1 - 7 from Mechanisms That Can Promote Peripheral B-cell Lymphoma in ATM-Deficient Mice
Authors: Tepsuporn Suprawee , Hu Jiazhi , Gostissa Monica , Alt Frederick W.
Published: April 2023

PDF file - 1803K, Figure S1. Additional Southern blot analyses of DA, AB, and DAB B cells lymphomas. Figure S2. Analysis of c-myc expression and locus rearrangements in ATM-deficient B cell lymphomas. Table S1. DA tumor mouse cohort with controls. Table S2. Summary of DA B cell lymphoma analyses. Table S3. AB tumor mouse cohort with controls. Table S4. Summary of AB B cell lymphoma analyses. Table S5. DAB tumor mouse cohort with controls. Table S6. Summary of DAB B cell lymphoma analyses. Table S7. Eight tumor translocation junctions and their closest cryptic RSSs.